Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 1998

View Archived Issues

Cephalon provides investor update on product development programs

MGI Pharma: Q2 1998 highlights

Interferon Sciences updates on status of Alferon N Injection clinical trials program

British Biotech: year-end 1998 highlights

Canadian patent covers Jenner's cancer vaccine

Low-dose tamoxifen reduces the risk of bone fracture in elderly women

Sepracor patents single-isomer form of zopiclone for treatment of sleep disorders

Idun to license patent application for apoptosis model

Cel-Sci reports herpes vaccines demonstrating efficacy in animals

Joint research project will evaluate ABS-103 for the treatment of epilepsy

Roche reports antiviral peptides, viral proteinase inhibitors

Taisho synthesizes antitumor prostaglandin analogues

Sankyo enhances pipeline of antibacterial agents with new discovery

Kissei describes AGE inhibitors for treating diabetic complications

More PDE IVA inhibitors in the pipeline at Kyowa Hakko

Pfizer investigates COX-2 inhibitors as potential antiinflammatory agents

NPY Y5 receptor antagonist suppresses feeding and reduces body weight in rodents

Antidepressant efficacy established with new addition to the Ampakine family

Endothelin ETA antagonist YM-598 undergoes preclinical testing at Yamanouchi

The peripheral vasodilator vintoperol has antioxidant action in vitro

NSAID from Sigma-Tau is devoid of GI side effects

Wound-healing efficacy of PGI2 analogue confirmed in preclinical models

AH-9700, a promising centrally and peripherally acting treatment for incontinence

Uriach describes antihypertensive activity and renal effects of AII blocker

New antimigraine drug candidate discussed by Pierre Fabre at IUPHAR meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Wuxi Apptec insists it’s ‘not a Chinese military company’
BioWorld
Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.